Gut (Bacteria) Check on Parkinson's: Role of Microbiome

This is an archived file of an event that took place January 19, 2017.

Our panelists discuss the role of gut bacteria in Parkinson's and how the microbiome (microorganisms that share our body space) may help us understand more about disease onset, progression and medication response. 

Title: Gut (Bacteria) Check on Parkinson's: Role of the Microbiome

Duration: 1 hour

Continuing Medical Education Information for Health Care Professionals

MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Date of Original Release: January 19, 2017
Date CME Credit No Longer Available: January 19, 2019

Learning Objectives
At the conclusion of this course, participants should be able to:

  • Define what is meant by the terms "gut bacteria" and "microbiome."
  • Explain why researchers investigate the gut in Parkinson's disease.
  • Discuss the possible connections between gut bacteria and Parkinson's disease.
  • Recognize the role diet plays in Parkinson's disease.
  • Identify how researchers could use findings in the gut to measure and/or treat Parkinson's disease.         

Target Audience
This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Faculty
Dave Iverson
Moderator
No disclosures

Jeff Bronstein MD, PhD
Professor of Neurology
Fred Silton Family Chair in Movement Disorders
Director of Movement Disorders
David Geffen School of Medicine at UCLA
No disclosures

Filip Scheperjans, MD, PhD
Neurologist
Helsinki University Hospital
Research Grants: Michael J Fox Foundation, Finnish Medical Foundation, Academy of Finland
Advisory Role: Herantis Pharma
Board Membership: NeuroInnovation Oy
Employment: Hospital District of Helsinki and Uusimaa
Honoraria: UCB
Ownership Interests: NeuroInnovation Oy
Patent Copyright License: WO2015/181449A1

Register

Already Registered?

*Required Fields.

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.